ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Utilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes
dc.contributor.author | Manikwar, Prakash | |
dc.contributor.author | Tejo, Bimo A. | |
dc.contributor.author | Shinogle, Heather E. | |
dc.contributor.author | Moore, David S. | |
dc.contributor.author | Zimmerman, Tahl | |
dc.contributor.author | Blanco, Francisco | |
dc.contributor.author | Siahaan, Teruna J. | |
dc.date.accessioned | 2011-06-15T14:36:34Z | |
dc.date.available | 2011-06-15T14:36:34Z | |
dc.date.issued | 2010-05-10 | |
dc.identifier.citation | Manikwar P, Tejo BA, Shinogle H, Moore DS, Zimmerman T, Blanco F, Siahaan TJ. Utilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes. Theranostics 2011; 1:277-289. | |
dc.identifier.uri | http://hdl.handle.net/1808/7609 | |
dc.description.abstract | The long-term objective of this project is to utilize the I-domain protein for the -subunit of LFA-1 to target drugs to lymphocytes by binding to ICAM receptors on the cell surface. The short-term goal is to provide proof-of-concept that I-domain conjugated to small molecules can still bind to and uptake by ICAM-1 on the surface of lymphocytes (i.e., Raji cells). To accomplish this goal, the I-domain protein was labeled with FITC at several lysine residues to produce the FITC-I-domain and CD spectroscopy showed that the FITC-I-domain has a secondary structure similar to that of the parent I-domain. The FITC-I-domain was taken up by Raji cells via receptor-mediated endocytosis and its uptake can be blocked by anti-I-domain mAb but not by its isotype control. Antibodies to ICAM-1 enhance the binding of I-domain to ICAM-1, suggesting it binds to ICAM-1 at different sites than the antibodies. The results in-dicate that fluorophore modification does not alter the binding and uptake properties of the I-domain protein. Thus, I-domain could be useful as a carrier of drug to target ICAM-1-expressing lymphocytes. | |
dc.language.iso | en_US | |
dc.publisher | Theranostics | |
dc.relation.isversionof | http://www.thno.org/v01p0277.htm | |
dc.rights | © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. | |
dc.rights.uri | http://creativecommons.org/ licenses/by-nc-nd/3.0/ | |
dc.subject | Icam-1 | |
dc.subject | Fitc-i-domain | |
dc.subject | Binding | |
dc.subject | Endocytosis | |
dc.subject | Raji cells | |
dc.title | Utilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes | |
dc.type | Article | |
kusw.kuauthor | Manikwar, Prakash | |
kusw.kuauthor | Siahaan, Teruna J. | |
kusw.kudepartment | Pharmaceutical Chemistry | |
kusw.oastatus | fullparticipation | |
dc.identifier.doi | 10.7150/thno/v01p0277 | |
kusw.oaversion | Scholarly/refereed, publisher version | |
kusw.oapolicy | This item meets KU Open Access policy criteria. | |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as: © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.